Experience

Davis Polk is advising Aetna on its approximately $77 billion acquisition by CVS Health. The transaction, which is expected to close in the second half of 2018, is subject to approval by…

Davis Polk is advising McKesson Corporation on its acquisition of RxCrossroads, a provider of tailored services to pharmaceutical and biotechnology manufacturers, from CVS Health…

Davis Polk is advising Advanced Accelerator Applications S.A. on its $3.9 billion acquisition by Novartis. Entry into the definitive agreement has been approved by the board of…

Davis Polk is advising PharMerica Corporation on its approximately $1.4 billion acquisition by a newly formed company controlled by KKR, with Walgreens Boots Alliance, Inc. as a minority…

Davis Polk is advising J.P. Morgan Securities LLC as financial adviser to LabCorp in connection with its approximately $1.2 billion acquisition of Chiltern International Ltd. The…

Davis Polk is advising Mitsubishi Tanabe Pharma Corporation on its approximately $1.1 billion acquisition of NeuroDerm Ltd. The transaction, which is expected to close in the fourth quarter…

Davis Polk is advising J.P. Morgan Securities LLC as financial adviser to The Spectranetics Corporation in connection with its acquisition by a wholly owned subsidiary of Royal Philips,…

Davis Polk is advising J.P. Morgan as financial adviser to Alere Inc. in connection with the amendment of the existing terms of its agreement for Abbott’s acquisition of Alere. Under the…

Davis Polk is advising JP Morgan as financial adviser to Teleflex Incorporated in connection with its approximately $1 billion acquisition of Vascular Solutions, Inc. The closing of the…

Davis Polk is advising Roche Holding Ltd. in connection with the sale of an active pharmaceutical ingredients manufacturing facility in Florence, South Carolina, to Patheon N.V. Under the…